Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Version 2 2024-06-02, 23:39Version 2 2024-06-02, 23:39
Version 1 2023-08-16, 03:52Version 1 2023-08-16, 03:52
journal contribution
posted on 2024-06-02, 23:39authored byS Peters, J-L Pujol, U Dafni, M Dómine, S Popat, M Reck, J Andrade, A Becker, D Moro-Sibilot, A Curioni-Fontecedro, O Molinier, K Nackaerts, A Insa Mollá, R Gervais, G López Vivanco, J Madelaine, J Mazieres, M Faehling, F Griesinger, M Majem, JL González Larriba, M Provencio Pulla, K Vervita, H Roschitzki-Voser, B Ruepp, P Mitchell, RA Stahel, C Le Pechoux, D De Ruysscher, Ann LivingstoneAnn Livingstone
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial